BUZZ-Bristol Myers drops after US judge rules co must face $6.7 bln lawsuit

Reuters12-02
BUZZ-Bristol Myers drops after US judge rules co must face $6.7 bln lawsuit 

** Shares of Bristol Myers Squibb BMY.N down 1.14% at $48.62 after U.S. judge rejects bid to dismiss $6.7 bln lawsuit over Celgene deal

** Judge allows UMB Bank to pursue claims on behalf of Celgene shareholders, alleging Bristol Myers breached contract and failed to act in good faith by delaying FDA approvals for three drugs, including cancer treatment Breyanzi

** Lawsuit stems from Bristol Myers’ $80.3 bln purchase of Celgene in 2019; shareholders who held "contingent value rights" $(CVR)$ were promised $9/share in cash if approvals met deadlines

** Breyanzi approval came five weeks late in Feb. 2021; judge says jury should decide if delisting CVRs violated implied agreement

** Bristol Myers did not immediately respond to requests for comment, while a lawyer for UMB declined to comment

** Including sessions' move, BMY shares down 13.1% YTD

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment